Publications (26) Publications de Antonio Muñoz Callejas

2024

  1. PSGL-1, ADAM8, and selectins as potential biomarkers in the diagnostic process of systemic lupus erythematosus and systemic sclerosis: an observational study

    Frontiers in Immunology, Vol. 15

  2. Regulation of monocyte apoptosis and DNA extrusion in monocyte extracellular traps by PSGL-1: Relevance in systemic lupus erythematosus

    Translational Research, Vol. 274, pp. 10-20

2023

  1. Analysis of the interstitial lung disease pathogenesis in PSGL-1 KO and P-Selectin KOmice

    44 Congreso de las Sociedad Española de Inmunología

  2. Diagnostic predictive value of soluble PSGL-1 and its ligands in patients with Systemicsclerosis (SSc)

    44 Congreso de las Sociedad Española de Inmunología

  3. Interstitial Lung Disease Associated with Systemic Sclerosis; New Molecules, New Routes of Administration

    JOURNAL OF PHARMACEUTICAL ANALYSIS, Vol. 12

  4. Low P-Selectin Glycoprotein Ligand-1 Expression in Neutrophils Associates with Disease Activity and Deregulated NET Formation in Systemic Lupus Erythematosus

    International Journal of Molecular Sciences, Vol. 24, Núm. 7, pp. 6144

  5. P-selectin/PSGL-1 axis regulation of autophagy in monocytes from healthy donors andlupus patients

    44 Congreso de las Sociedad Española de Inmunología

  6. PSGL-1/P-selectin interaction reduces the amount of DNA released in monocytesextracelular traps: lack of regulation in SLE patients

    44 Congreso de las Sociedad Española de Inmunología

2022

  1. Characterization of interstitial lung disease present in PSelectin KO mice (Lupus-likesyndrome) and PSGL-1 KO mice (Scleroderma-like syndrome)

    43 Congreso de las Sociedad Española de Inmunología

  2. PSGL-1/P-selectin axis in the homeostasis of monocytes from healthy donors, lupus andscleroderma patients

    43 Congreso de las Sociedad Española de Inmunología

  3. Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice

    British Journal of Pharmacology, Vol. 179, Núm. 18, pp. 4534-4548

2021

  1. Efecto del everolimus en el tratamiento de la neumonía intersticial asociada a esclerosissistémica en ratones PSGL-1 KO

    42 Congreso de la Sociedad Española de Inmunología

  2. IGF-1 facilitates extinction of conditioned fear

    eLife, Vol. 10

  3. Intratracheal Instillation of Everolimus Included In HA-decorated Liposomes, as SSc-ILDTreatment in mice

    Nanotechnology and Chronic Diseases

  4. Lung targeted delivery of Everolimus as a new treatment of Scleroderma-relatedinterstitial lung disease (SSC-ILD) developed by PSGL-1 KO mice

    Annual European Congress of Rheumatology EULAR 2021

  5. PSGL-1/P-Selectin interaction controls generation of NETs in human neutrophils

    42 Congreso de la Sociedad Española de Inmunología

  6. Signaling of PSGL-1 in human neutrophils might control NET generation and apoptosisand might be altered in SLE patients

    Annual European Congress of Rheumatology EULAR 2021

  7. miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease

    Archivos de Bronconeumología (English Edition), Vol. 57, Núm. 7, pp. 457-463

2020

  1. Estudio preliminar del tratamiento con Everolimus de la neumonía intersticial asociada aesclerosis sistémica en ratones PSGL-1 KO

    XLVI Congreso Nacional de la SER

  2. Relevance of PSGL-1 Expression in B Cell Development and Activation

    Frontiers in Immunology, Vol. 11